Sökning: onr:"swepub:oai:DiVA.org:uu-81295" >
Phase II study of c...
Phase II study of capecitabine in combination with paclitaxel in patients with anthracycline-pretreated advanced/metastatic breast cancer.
-
Batista, N (författare)
-
Perez-Manga, G (författare)
-
Constenla, M (författare)
-
visa fler...
-
Ruiz, A (författare)
-
Carabantes, F (författare)
-
Castellanos, J (författare)
-
Gonzalez Baron, M (författare)
-
Villman, K (författare)
-
Söderberg, M (författare)
-
- Ahlgren, J (författare)
- Uppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi,Centrum för klinisk forskning, Gävleborg
-
Casinello, J (författare)
-
Regueiro, P (författare)
-
Murias, A (författare)
-
visa färre...
-
(creator_code:org_t)
- 2004
- 2004
- Engelska.
-
Ingår i: Br J Cancer. - 0007-0920. ; 90:9, s. 1740-6
- Relaterad länk:
-
http://www.ncbi.nlm....
-
visa fler...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- The addition of oral capecitabine to docetaxel improves response rate, time to progression (TTP) and overall survival in anthracycline-pretreated metastatic breast cancer (MBC). This phase II study evaluates the efficacy and safety of a 21-day cycle of oral capecitabine (1000 mg m(-2) twice daily, days 1-14) plus i.v. paclitaxel (175 mg m(-2), day 1) in anthracycline-pretreated advanced/MBC. In all, 73 patients were enrolled at 13 Swedish and Spanish centres. The objective response rate was 52% (95% confidence interval (CI): 40-63%) in the intent-to-treat population, including complete responses in 11%. Disease was stabilised in a further 29%. The median time to disease progression (TTP) was 8.1 months and the median overall survival was 16.5 months. The combination was generally well tolerated with a predictable safety profile. The most common treatment-related nonhaematological adverse events were hand-foot syndrome (42%), alopecia (30%) and diarrhoea (26%). The only treatment-related Grade 3/4 adverse events occurring in >5% of patients were alopecia (22%) and hand-foot syndrome (11%). Grade 3/4 neutropenia and lymphocytopenia were reported in 12 and 14% of patients, respectively. Capecitabine plus paclitaxel is highly active with a favourable safety profile in anthracycline-pretreated MBC.
Nyckelord
- Adolescent
- Adult
- Aged
- Anthracyclines/therapeutic use
- Antineoplastic Agents/therapeutic use
- Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
- Breast Neoplasms/*drug therapy/mortality
- Deoxycytidine/administration & dosage/adverse effects/*analogs & derivatives
- Disease Progression
- Female
- Humans
- Maximum Tolerated Dose
- Middle Aged
- Paclitaxel/administration & dosage/adverse effects
- Survival Rate
- Treatment Outcome
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Batista, N
-
Perez-Manga, G
-
Constenla, M
-
Ruiz, A
-
Carabantes, F
-
Castellanos, J
-
visa fler...
-
Gonzalez Baron, ...
-
Villman, K
-
Söderberg, M
-
Ahlgren, J
-
Casinello, J
-
Regueiro, P
-
Murias, A
-
visa färre...
- Artiklar i publikationen
-
Br J Cancer
- Av lärosätet
-
Uppsala universitet